作者: Rodolphe Maheux , Chantal Guilloteau , André Lemay , Adrien Bastide , Atilla T.A. Fazekas
DOI: 10.1016/0002-9378(85)90554-X
关键词: Uterine leiomyoma 、 Hormone 、 Endocrinology 、 Follicle-stimulating hormone 、 Luteinizing hormone 、 Uterine Hemorrhage 、 Internal medicine 、 Medicine 、 Buserelin 、 Agonist 、 Leiomyoma
摘要: Ten women with 12 uterine leiomyomas ranging from 7.5 to 420 cc (mean, 112.6 +/- 39.4) were treated subcutaneous injections of the luteinizing hormone-releasing hormone agonist buserelin, 200 micrograms three times daily for 1 week and then 500 rest 6-month treatment period. Following initial stimulation pituitary ovarian axis was suppressed after 3 weeks mean serum estradiol between 17 36 pg/ml. Seven had a marked regression in size following agonist; two undetectable volume other five diminished by an average 80%. One tumor did not respond treatment, regressed 25%, two, reduction 65% 50%, reenlarged during last 2 months 75% 100% respectively their volume. Luteinizing is first medication demonstrated effective reducing myomas.